Johnson & Johnson, made the victory over Pfizer Inc.’s consumer health care unit for a price of $16.6 billion.
Bill Weldon, J&J’s CEO, says
The company is assembling a leadership team ‘to see how everything fits together’.
Marketing and branding experts are predicting that New Brunswick based health care giant Johnson & Johnson using its sense to boost the sales of mature Pfizer products among customers. They will make perfect matching between Pfizer’s brands and their own brands.
Last year Pfizer sold $3.9 billion consumer health care products worldwide while J&J’s $9.1 billion.
Pfizer and J&J together sold $6.35 billion in consumer health products in the U.S, which is 20% of the $33.4 billion of U.S. sales.
Another benefit of this deal is that both companies have competing products. Meanwhile, J&J can save money because it will need less manufacturing plants.
Once this deal will get approval by the host of regulators, the J&J will also get the U.S. rights to switch on number1 position.
Via: Courier News
